PharmTech Drug Digest 11.20
News|Articles|October 3, 2018

Medherant Receives Grant from Innovate UK for Transdermal Patch Manufacturing

Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.

Medherant, a developer of innovative transdermal drug delivery treatments for pain and central nervous system diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK, the company announced in an Oct. 3, 2018 press release. The grant will enable the company to buy equipment and move forward with its plans to extend its pilot-scale manufacture of patches formulated with its unique TEPI Patch technology to GMP manufacture for clinical trials. 

The patent-protected patch technology enables the development of drug-in-adhesive patch products with better adhesion and more efficient delivery of drugs through the skin over a prolonged period. Medherant's first product, an ibuprofen TEPI Patch, is in Phase I clinical development with initial results expected in Q4 2018. Medherant's business model is to develop products to then out-license to established pharmaceutical companies for commercialization.

Medherant recently installed its own pilot-scale patch manufacturing plant and has successfully produced non-GMP patches of the ibuprofen TEPI Patch. The company has also produced patches for third parties interested in assessing the suitability of the TEPI technology for their drugs. Medherant’s high-throughput permeation assessment process rapidly identifies formulations that meet the target drug release profile, enabling the creation of candidate patch formulations in only two to three months.

Source: Medherant


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.